-
-
-
-
-
-
-
MannKind outlines 2026 growth drivers with multiple FDA decisions pending
-
-
-
-
-
-
-
MannKind (MNKD) PT Raised to $8 at RBC Capital
-
-
-
-
-
-
-
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
-
-
-
-
-
-
-
MannKind (MNKD) PT Raised to $6.50 at Oppenheimer
-
-
-
-
-
-
-
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
-
-
-
-
-
-
-
MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.
-
-
-
-
-
-
-
Pre-Open Movers 05/17: (CRAY) (ACHN) (UA) Higher; (PINS) (BIDU) (IQ) (more...)
-
1,182,407 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

